Research programme: tryptamine based therapeutics - PsyBio Therapeutics
Alternative Names: Tryptamines - PsyBio TherapeuticsLatest Information Update: 28 Jun 2024
At a glance
- Originator PsyBio Therapeutics
- Class Antidepressants; Anxiolytics; Biogenic monoamines; Drug withdrawal therapies; Indoles; Neuropsychotherapeutics; Small molecules; Tryptamines
- Mechanism of Action Serotonin 5-HT2A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Anxiety disorders; Depressive disorders; Post-traumatic stress disorders; Substance-related disorders
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for preclinical development in Anxiety-disorders in USA
- 28 Jun 2024 No recent reports of development identified for preclinical development in Depressive disorders in USA
- 28 Jun 2024 No recent reports of development identified for preclinical development in Post-traumatic-stress-disorders in USA